

Later Metabolic Risk after Nutritional Supplements in Infants Born Early or Small: An Individual Participant Data Meta-Analysis (ESSENCE IPD-MA)

Lin L, Gamble GD, Crowther CA, Bloomfield FH, Harding JE for the ESSENCE IPD-MA Group Liggins Institute, University of Auckland, Auckland, New Zealand






# Background

Supplementing nutrition in infants born small is associated with improved early growth and cognitive outcomes, but may increase risk of later metabolic disease. Effects may also differ by sex.

# Objective

To assess the sex-specific effects of macronutrient supplements in nutrition of preterm and small-forgestational-age infants on their development and metabolism after hospital discharge.

### Fig 1. Study selection



# Methodology

#### Study design

Individual participant data meta-analysis (IPD-MA)

# Type of studies Randomised or quasi-randomised trials.

### Population

Infants born preterm or small (<2.5 kg or <10th centile).

### Intervention

Supplements to increase the intake of one or more macronutrients with the primary aim of improving growth and development.

#### Primary outcome

Any metabolic risk (obesity, type-2 diabetes, highdensity and low-density lipoproteins, triglycerides, cholesterol, fasting glucose, systolic, diastolic and mean blood pressure and body mass index).


- post-discharge data
- 55 trials (88 records) without published post-discharge data

21 trials shared data with the ESSENCE **IPD-MA** collaboration

1 Wrong patient population 2 Letter/ comment 3 Unable to locate

5 trials have long-term metabolic outcomes

### Fig 2. Forest plots of metabolic risk at different ages



# Analysis


- One-stage analyses accounting for the clustering of participants within studies.
- Sex effects explored using subgroup analyses and interaction terms.

# Results


Twenty-one trials from 12 different countries shared data with the ESSENCE IPD-MA collaboration, and 5 trials have long-term metabolic outcomes (Fig 1).

Supplementation did not alter any metabolic risk in

- childhood (3-8 years, 3 trials, n=334; aRR 1.02, 95% CI 0.77, 1.35, P=0.90),
- adolescence (9-18 years, 2 trials, n=104; aRR 0.86, 95% CI 0.64, 1.16, P=0.31), or



Metabolic risk in childhood, in adolescence or at >3 years adjusting for sex, gestational age and birth weight z-scores. P-value for heterogeneity in childhood = 0.23, in adolescence = 0.15, at >3 years = 0.07.



#### Fig 3. Forest plots of metabolic risk in girls and boys separately

- at >3 years (5 trials, n=438; aRR 0.94, 95% CI 0.76, 1.17, P=0.59) (Fig 2), and there was no significant sex interaction (Fig 3).
- In childhood, children in the supplemented group had lower triglyceride concentrations (1 trial, n=207, adjusted mean difference (mmol/L) -0.12, 95% CI -0.23, -0.01, P = 0.03).
- There were no differences for any other metabolic outcomes, no significant sex interaction, and no significant heterogeneity.

Metabolic risk for boys and girls adjusted for gestational age and birth weight z-scores.

# Conclusions

Contrary to observational studies, IPD of randomised trials shows early macronutrient supplementation for infants born small does not increase later metabolic risk.